214 related articles for article (PubMed ID: 12174942)
1. Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha.
Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Ikeda K; Soma G; Fukushima T
Anticancer Res; 2002; 22(4):2447-53. PubMed ID: 12174942
[TBL] [Abstract][Full Text] [Related]
2. Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas.
Fukushima T; Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Soma G
Anticancer Res; 2003; 23(6a):4473-81. PubMed ID: 14666736
[TBL] [Abstract][Full Text] [Related]
3. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704
[TBL] [Abstract][Full Text] [Related]
4. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Fukushima T; Yamamoto M; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 1998; 18(5D):3965-70. PubMed ID: 9854511
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and feasibility of procarbazine, ranimustine and vincristine chemotherapy, and the role of surgical resection in anaplastic oligodendroglioma.
Yamamoto M; Iwaasa M; Nonaka M; Tsugu H; Nabeshima K; Fukushima T
Anticancer Res; 2005; 25(6A):3715-23. PubMed ID: 16302731
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
Watanabe K; Kanaya H; Fujiyama Y; Kim P
Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
Afra D; Sipos L; Vitanovics D
Ideggyogy Sz; 2002 Jan; 55(1-2):38-44. PubMed ID: 12122942
[TBL] [Abstract][Full Text] [Related]
8. [A clinical evaluation of combination therapy with radiation, MCNU, carboplatin and IFN-beta or with radiation, MCNU, carboplatin, etoposide and IFN-beta for malignant gliomas].
Mizumatsu S; Matsumoto K; Maeda Y; Tamiya T; Furuta T; Ohmoto T
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2055-60. PubMed ID: 9838907
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of high-dose chemotherapy with autologous stem cell transplantation for patients with malignant astrocytomas.
Chen B; Ahmed T; Mannancheril A; Gruber M; Benzil DL
Cancer; 2004 May; 100(10):2201-7. PubMed ID: 15139065
[TBL] [Abstract][Full Text] [Related]
11. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
Soffietti R; Nobile M; Rudà R; Borgognone M; Costanza A; Laguzzi E; Mutani R
Cancer; 2004 Feb; 100(4):807-13. PubMed ID: 14770438
[TBL] [Abstract][Full Text] [Related]
12. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
[TBL] [Abstract][Full Text] [Related]
13. High-dose carboplatin with etoposide in patients with recurrent thymoma: the Indiana University experience.
Hanna N; Gharpure VS; Abonour R; Cornetta K; Loehrer PJ
Bone Marrow Transplant; 2001 Sep; 28(5):435-8. PubMed ID: 11593315
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of the expression of endothelial-monocyte activating polypeptide II (EMAPII) in the treatment of glioblastoma with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Yamamoto M; Fukushima T; Ueno Y; Hayashi S; Kimura H; Soma G; Tomonaga M
Anticancer Res; 2000; 20(6A):4081-6. PubMed ID: 11131676
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma.
Buckner JC; Brown LD; Cascino TL; Gerstner JB; Krook JE; Westberg MW; Wiesenfeld M; O'Fallon JR; Scheithauer B
J Neurooncol; 1990 Dec; 9(3):249-54. PubMed ID: 2086739
[TBL] [Abstract][Full Text] [Related]
17. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
18. Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: a report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94.
Fuchs J; Bode U; von Schweinitz D; Weinel P; Erttmann R; Harms D; Mildenberger H
Klin Padiatr; 1999; 211(4):305-9. PubMed ID: 10472567
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
Rao RD; Krishnan S; Fitch TR; Schomberg PJ; Dinapoli RP; Nordstrom K; Scheithauer B; O'Fallon JR; Maurer MJ; Buckner JC
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):380-6. PubMed ID: 15667956
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
